Alerts
COVID-19 update
See our updated visitor policy, which now allows 1 visitor per patient during exams only. No visitors are allowed in treatment (applies at all locations). Only exceptions are patients with physical or mental disability.
Skip Navigation

A Phase I/IB First-In-Human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-Tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination with Cemiplimab in Adult Patients with Advanced Solid Tumors

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT03192345

Study #:
STUDY00141226

Start Date:
Nov 05, 2017

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03192345

View Complete Trial Details & Eligibility at ClinicalTrials.gov